Skip to main content
. 2011 Oct 15;204(8):1191–1201. doi: 10.1093/infdis/jir505

Figure 3.

Figure 3.

In low HIV RNA stratum, (A) Time to tolerability endpoint, defined as first change in regimen; and (B) time to first primary safety endpoint, defined as first grade 3 or 4 sign, symptom, or laboratory abnormality while on initial randomized treatment that was at least 1 grade higher than baseline, excluding hyperbilirubinemia and elevation in the creatine kinase level.